UBS Group
KITE

UBS Group’s Kite Pharma, Inc. KITE Stock Holding History

UBS Group’s Portfolio KITE Stock Details KITE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,500
Closed -$259K – 8272
2017
Q2 		$259K Buy
+2,500
New +$204K ﹤0.01% 4576
2015
Q3 		– Sell
-100
Closed -$6K – 8865
2015
Q2 		$6K Sell
100
-1,600
-94% -$91.3K ﹤0.01% 7824
2015
Q1 		$98K Hold
1,700
– – ﹤0.01% 5436
2014
Q4 		$98K Buy
+1,700
New +$71.6K ﹤0.01% 5725

UBS Group's KITE Position: Q4 2017 in Review

UBS Group sold out of Kite Pharma, Inc. (KITE) in Q4 2017, closing a stake of 226,458 shares — an estimated $40.7M sold.

UBS Group first reported a position in KITE in Q4 2014 and held it in 12 quarters. The position peaked at $40.7M in Q3 2017. 0 funds tracked by Wall St. Rank hold KITE as of Q4 2017.

  • UBS Group reported no remaining Kite Pharma, Inc. position as of Q4 2017 after selling out during the quarter.
  • UBS Group sold 226,458 Kite Pharma, Inc. shares in Q4 2017, an estimated $40.7M.
  • UBS Group first reported a position in Kite Pharma, Inc. in Q4 2014 and held it in 12 quarters.
  • UBS Group's Kite Pharma, Inc. position peaked at $40.7M in Q3 2017.
  • 0 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q4 2017.

Based on UBS Group's 13F filing for Q4 2017, filed 14 Feb 2018.